Osteonecrosis of the jaw associated with pembrolizumab.

Abstract

We report a case of osteonecrosis of the jaw (ONJ) with pembrolizumab, a rare yet possibly emerging complication. In this case, a temporal relationship between the development of ONJ and the patient's treatment regimen suggested an association between pembrolizumab/GVD therapy and the development of ONJ. Thrombocytosis and anatomic factors may also have played a role. The number of patients using pembrolizumab will likely continue to increase. We document this instance in order to better inform dental treatment around cancer patients undergoing pembrolizumab therapy.

• Authors: Isabel Pennings, Alison Moskowitz, Gunjan Shah, Cherry Estilo, Joseph M Huryn, SaeHee K Yom
• Journal: Oral surgery, oral medicine, oral pathology and oral radiology (Oral Surg Oral Med Oral Pathol Oral Radiol) Vol. 136 Issue 1 Pg. e11-e14 (07 2023) ISSN: 2212-4411 [Electronic] United States
• PMID: 36804060 (Publication Type: Case Reports, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Diphosphonates
• Bone Density Conservation Agents
• pembrolizumab

Topics

• Humans
• Diphosphonates (adverse effects)
• Bone Density Conservation Agents (adverse effects)
• Jaw Diseases (complications)
• Osteonecrosis (complications)
• Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology)
• Jaw